Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Ravulizumab in Older Patients Aged >65 Years with Paroxysmal Nocturnal Hemoglobinuria in the 301 and 302 Phase 3 Extension Studies

Regis Peffault De Latour, MD PhD, Jeffrey Szer, MBBS, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Jin Seok Kim, MD PhD, Caroline I. Piatek, MD, Alexander D. Kulagin, MD PhD, Anita Hill, Jimmy Wang, Ji Yu, Masayo Ogawa, MD FAAP, Hubert Schrezenmeier, Jong Wook Lee, MD, PhD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-140777

Published: 2020

Journal Articles

Efficacy and Safety of Concomitant Use of Ravulizumab and IST in Patients with Paroxysmal Nocturnal Hemoglobinuria up to 52 Weeks

Hubert Schrezenmeier, Jong Wook Lee, MD, PhD, Anita Hill, Vadim V Ptushkin, Viviani Pessoa, Rosario Notaro, Jimmy Wang, Masayo Ogawa, MD FAAP, Shinichiro Okamoto, MD PhD, Lily LL Wong, MD FRCPath, Regis Peffault De Latour, MD PhD, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-142453

Published: 2020

Journal Articles

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Anita Hill, MD PhD, Saskia Langemeijer, MD PhD, Richard A. Wells, MD DPhil, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Emilio Ojeda Gutierrez, Caroline I. Piatek, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Kensuke Usuki, Alberto Bosi, Robert A. Brodsky, MD, Masayo Ogawa, MD FAAP, Ji Yu, Stephan Ortiz, RPh, PhD, Alexander Röth, MD PhD, Jong-Wook Lee, MD PhD, Régis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 2231.

https://doi.org/10.1182/blood-2019-128746

Published: 2019

Journal Articles

The Global aHUS Registry: Characteristics of 826 Patients with Atypical Hemolytic Uremic Syndrome

Christoph Licht, MD FRCP(C), FASN, Gianluigi Ardissino, MD PhD, Gema Ariceta, MD PhD, David J. Cohen, MD, Christoph Gasteyger, MD, Laurence A. Greenbaum, MDPhD, Masayo Ogawa, MD FAAP, Varant Kupelian, PhD, Franz Schaefer, MD, Johan Vande Walle, MD PhD, Véronique Frémeaux-Bacchi, MD PhD

Blood (2015) 126 (23): 4640.

https://doi.org/10.1182/blood.V126.23.4640.4640

Published: 2015

Journal Articles

Baseline Demographics and Characteristics of 466 Patients with Atypical Hemolytic Uremic Syndrome in the Global aHUS Registry

Christoph Licht, MD FRCP(C), FASN, Gianluigi Ardissino, MD PhD, Gema Ariceta, MD PhD, David Cohen, MD, Christoph Gasteyger, MD, Laurence A. Greenbaum, MDPhD, Masayo Ogawa, MD FAAP, Franz Schaefer, MD, Johan Vande Walle, MD PhD, Veronique Fremeaux-Bacchi, MD PhD

Blood (2014) 124 (21): 4204.

https://doi.org/10.1182/blood.V124.21.4204.4204

Published: 2014

Journal Articles

Eculizumab Inhibits Thrombotic Microangiopathy and Improves Renal Function in Pediatric Patients with Atypical Hemolytic Uremic Syndrome: 1-Year Update

Laurence A. Greenbaum, MDPhD, Marc Fila, MD PhD, Gianluigi Ardissino, MD PhD, Samhar I. Al-Akash, MD, Jonathan H Evans, MD, Kenneth Lieberman, MD, Silvio Maringhini, MD, Lars Pape, MD, Lesley Rees, MD FRCPCH, Nicole C.A.J. van de Kar, MD PhD, Johan Vande Walle, MD PhD, Masayo Ogawa, MD FAAP, Camille L. Bedrosian, MD, Christoph Licht, MD FRCP(C), FASN

Blood (2014) 124 (21): 4986.

https://doi.org/10.1182/blood.V124.21.4986.4986

Published: 2014

Journal Articles

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Adult Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Fadi Fakhouri, Maryvonne Hourmant, MD, Spero R. Cataland, M.D., Mario Espinosa, A. Osama Gaber, Jan Menne, Enrico Minetti, Francois Provot, Eric Rondeau, Piero Ruggenenti, Laurent Weekers, Masayo Ogawa, MD, FAAP, Camille L. Bedrosian, MD, Christophe Legendre

Blood (2013) 122 (21): 2179.

https://doi.org/10.1182/blood.V122.21.2179.2179

Published: 2013

Journal Articles

Biomarkers Of Complement and Endothelial Activation, Inflammation, Thrombosis and Renal Injury In Patients (pts) With aHUS Treated With Eculizumab (ECU)

Roxanne Cofiell, Anjli Kukreja, PhD, Krystin Bedard, Yan Yan, Angela Mickle, Masayo Ogawa, MD, FAAP, Camille L. Bedrosian, MD, Susan Faas, PhD

Blood (2013) 122 (21): 2184.

https://doi.org/10.1182/blood.V122.21.2184.2184

Published: 2013

Journal Articles

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Pediatric Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Larry Greenbaum, MD, Marc Fila, Gianluigi Ardissino, Samhar Al-Akash, Jonathan Evans, Paul Henning, Kenneth Lieberman, Silvio Maringhini, Lars Pape, Lesley Rees, Nicole Kar, Johan Vande Walle, Masayo Ogawa, MD, FAAP, Camille L. Bedrosian, MD, Christoph Licht, MD

Blood (2013) 122 (21): 2191.

https://doi.org/10.1182/blood.V122.21.2191.2191

Published: 2013

Journal Articles

Efficacy and Safety of Eculizumab in Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria

Ulrike M. Reiss, MD, Jeffrey Schwartz, MD, Kathleen M Sakamoto, MD, PhD, Geetha Puthenveetil, Masayo Ogawa, MD, FAAP, Russell E. Ware, MD, PhD

Blood (2011) 118 (21): 1034.

https://doi.org/10.1182/blood.V118.21.1034.1034

Published: 2011

NARROW

Efficacy and Safety of Ravulizumab in Older Patients Aged >65 Years with Paroxysmal Nocturnal Hemoglobinuria in the 301 and 302 Phase 3 Extension Studies

Efficacy and Safety of Concomitant Use of Ravulizumab and IST in Patients with Paroxysmal Nocturnal Hemoglobinuria up to 52 Weeks

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

The Global aHUS Registry: Characteristics of 826 Patients with Atypical Hemolytic Uremic Syndrome

Baseline Demographics and Characteristics of 466 Patients with Atypical Hemolytic Uremic Syndrome in the Global aHUS Registry

Eculizumab Inhibits Thrombotic Microangiopathy and Improves Renal Function in Pediatric Patients with Atypical Hemolytic Uremic Syndrome: 1-Year Update

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Adult Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Biomarkers Of Complement and Endothelial Activation, Inflammation, Thrombosis and Renal Injury In Patients (pts) With aHUS Treated With Eculizumab (ECU)

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Pediatric Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Efficacy and Safety of Eculizumab in Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only